GlobeNewswire·May 5, 2026, 4:05 PM ET

Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates

FDA granted Breakthrough Therapy designation to zovegalisib for PIK3CA-mutant, HR+/HER2- advanced breast cancer in the Phase 3 ReDiscover-2 trial population
Phase 3 dose data for zovegalisib doublet in CDK4/6-experienced patients showed 11.1-month median PFS with similar efficacy across kinase & non-kinase mutations
Zovegalisib plus atirmociclib selected as go-forward triplet regimen for 1L breast cancer with Phase 3 trial in endocrine-sensitive patients expected to start in early 2027
Pfizer agreed to supply atirmociclib for the upcoming Phase 3 1L trial while Relay Therapeutics retains full global rights to zovegalisib
Phase 1/2 trial initiated for RLY-8161, an NRAS-selective inhibitor, in patients with NRAS-mutant solid tumors including melanoma
Initial vascular anomalies clinical data conference call planned for May 19 during the ISSVA World Congress 2026
Cash, cash equivalents & investments totaled $642.1 million as of March 31, 2026, sufficient to fund operations into 2029
First quarter 2026 revenue was $3.0 million compared to $7.7 million in the prior year period under a license agreement with Elevar Therapeutics
Research & development expenses were $70.6 million for the quarter, down from $73.8 million in the prior year
General & administrative expenses were $11.0 million for the quarter, down from $18.7 million in the prior year
Net loss for the first quarter of 2026 was $73.3 million, or $0.41 per share, compared to $77.1 million in the prior year